INFECTIOUS DISEASES / CLINICAL RESEARCH
 
KEYWORDS
TOPICS
ABSTRACT
Introduction:
After 3 years of the pandemic, predictors of COVID-19 severity in children are still not completely known. This study was designed to define the high-risk group in hospitalized children.

Material and methods:
The analysis covered 2338 children in two centers. Among patients with a severe course, three groups were identified: requiring and not requiring mechanical ventilation, and those who died.

Results:
The median age of 70 children (54% female) with severe COVID-19 was 32 months. In 43 (61%) children, comorbidities were present. No one was vaccinated against COVID-19. On admission, medium SpO2 was 89%. Sixty-five (93%) patients presented with dyspnea, and 49 (70%) with cough. Fifty-three (76%) children required noninvasive oxygen support and 17 (24%) mechanical ventilation. Eight (11%) children died. The most significant difference between mechanically ventilated children who recovered and those who died was age – 124 vs, 12.8 months (p < 0.001). Children requiring mechanical ventilation presented higher C-reactive protein (CRP) (median 33.4 vs. 6.7 mg/dl), lactate dehydrogenase (LDH), and ferritin. In children who died even higher CRP (55.9 vs. 7.9 mg/dl), deep lymphopenia (0.65 vs. 1.85 × 103/µl), and thrombocytopenia (7 vs. 237 × 103/µl) were observed.

Conclusions:
Risk factors for a severe course of COVID-19 were: young age, lack of COVID-19 vaccination, auscultation changes and dyspnea at admission. The presence of comorbidities, high CRP, LDH, and ferritin levels were the predictors of need for mechanical ventilation and death. Among children mechanically ventilated, teenagers generally had a favorable prognosis of recovery, whereas infants with comorbidities were at the highest risk of death.
REFERENCES (37)
1.
O’Driscoll M, Ribeiro Dos Santos G, Wang et al. Age-specific mortality and immunity patterns of SARS-CoV-2. Nature 2021; 590: 140-5.
 
2.
CDC Data. Available from: https://data.cdc.gov/d/9bhg-hc.... Accessed March 15, 2023.
 
3.
Coronavirus (COVID-19) Latest Insights: Deaths. https://www.ons.gov.uk/peoplep.... Accessed March 15, 2023.
 
4.
COVID-19: Management in children. Available from: https://www.uptodate.com/conte.... Accessed March 15, 2023.
 
5.
Demographic Trends of COVID-19 cases and deaths in the US reported to CDC. Available from: https://covid.cdc.gov/covid-da.... Accessed March 15, 2023.
 
6.
COVID-19: Clinical manifestations and diagnosis in children. Available from: https://www.uptodate.com/conte.... Accessed March 15, 2023.
 
7.
Chiotos K, Hayes M, Kimberlin DW, et al. Multicenter interim guidance on use of antivirals for children with coronavirus disease 2019/severe acute respiratory syndrome coronavirus 2. J Pediatric Infect Dis Soc 2021; 10: 34-48.
 
8.
WHO Recommendations for national SARS-CoV-2 testing strategies and diagnostic capacities. Available from: https://www.who.int/publicatio.... Accessed March 15, 2023.
 
9.
Polish National Institute of Public Health Recommendations on SARS-Cov2 Laboratory Diagnostics. Available from: https://www.pzh.gov.pl/koronaw.... Accessed March 15, 2023.
 
10.
EMA Summary of Product Characteristics Veklury 100 mg. Available from: https://www.ema.europa.eu/en/d.... Accessed March 15, 2023.
 
11.
Fact sheet for healthcare providers Emergency Use Authorization (EUA) of Veklury® (remdesivir) for the treatment of coronavirus disease 2019 (Covid-19) in pediatric patients weighing 3.5 kg to less than 40 kg or pediatric patients less than 12 years of age weighing at least 3.5 kg, with positive results of direct Sars-cov-2 viral testing who are: hospitalized, or not hospitalized and have mild-to-moderate Covid-19, and are at high risk for progression to severe Covid-19, including hospitalization or death. Available from: https://www.fda.gov/media/1375.... Accessed March 15, 2023.
 
12.
National Institutes of Health. Coronavirus Disease 2019 (COVID-19) Treatment Guidelines. Available from: https://www.covid19treatmentgu.... Accessed March 15, 2023.
 
13.
WHO Living guidance for clinical management of COVID-19. Available from: https://apps.who.int/iris/bits.... Accessed March 15, 2023.
 
14.
Zachariah P, Johnson CL, Halabi KC, et al. Epidemiology, clinical features, and disease severity in patients with coronavirus disease 2019 (COVID-19) in a Children’s Hospital in New York City, New York. JAMA Pediatr 2020; 174: e202430.
 
15.
Dong Y, Mo X, Hu Y, et al. Epidemiology of COVID-19 among children in China. Pediatrics 2020; 145: e20200702.
 
16.
Armin S, Mirkarimi M, Pourmoghaddas Z, et al. Evidence-based prediction of COVID-19 severity in hospitalized children. Int J Clin Pract 2022; 2022: 1918177.
 
17.
Choi JH, Choi SH, Yun KW. Risk factors for severe COVID-19 in children: a systematic review and meta-analysis. J Korean Med Sci 2022; 37: e35.
 
18.
Kara AA, Böncüoğlu E, Kıymet E, et al. Evaluation of predictors of severe-moderate COVID-19 infections at children: a review of 292 children. J Med Virol 2021; 93: 6634-40.
 
19.
Woodruff RC, Campbell AP, Taylor CA, et al. Risk factors for severe COVID-19 in children. Pediatrics 2022; 149: e2021053418.
 
20.
Shekerdemian LS, Mahmood NR, Wolfe KK, et al. Characteristics and outcomes of children with coronavirus disease 2019 (COVID-19) infection admitted to US and Canadian pediatric intensive care units. JAMA Pediatr 2020; 174: 868-73.
 
21.
Williams N, Radia T, Harman K, Agrawal P, Cook J, Gupta A. COVID-19 Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection in children and adolescents: a systematic review of critically unwell children and the association with underlying comorbidities. Eur J Pediatr 2021; 180: 689-97.
 
22.
Preston LE, Chevinsky JR, Kompaniyets L, et al. Characteristics and disease severity of US children and adolescents diagnosed with COVID-19. JAMA Netw Open 2021; 4: e215298.
 
23.
González-Dambrauskas S, Vásquez-Hoyos P, Camporesi A, et al. Pediatric critical care and COVID-19. Pediatrics 2020; 146: e20201766.
 
24.
Götzinger F, Santiago-García B, Noguera-Julián A, et al. COVID-19 in children and adolescents in Europe: a multinational, multicentre cohort study. Lancet Child Adolesc Heal 2020; 4: 653-61.
 
25.
Marlais M, Wlodkowski T, Vivarelli M, et al. The severity of COVID-19 in children on immunosuppressive medication. Lancet Child Adolesc Health 2020; 4: e17-8.
 
26.
Sengler C, Eulert S, Minden K, et al. Clinical manifestations and outcome of SARS-CoV-2 infections in children and adolescents with rheumatic musculoskeletal diseases: data from the National Paediatric Rheumatology Database in Germany. RMD Open 2021; 7.
 
27.
Calvo C, Udaondo C. COVID-19 in children with rheumatic diseases in the Spanish National Cohort EPICO-AEP. J Rheumatol 2021; 48: 1190-2.
 
28.
Mukkada S, Bhakta N, Chantada GL, et al. Global characteristics and outcomes of SARS-CoV-2 infection in children and adolescents with cancer (GRCCC): a cohort study. Lancet Oncol 2021; 22: 1416-26.
 
29.
Haeusler GM, Ammann RA, Carlesse F, et al. SARS-CoV-2 in children with cancer or after haematopoietic stem cell transplant: an analysis of 131 patients. Eur J Cancer 2021; 159: 78-86.
 
30.
Millen GC, Arnold R, Cazier JB, et al. COVID-19 in children with haematological malignancies. Arch Dis Child 2022; 107: 186-8.
 
31.
Parri N, Magistà AM, Marchetti F, et al. Characteristic of COVID-19 infection in pediatric patients: early findings from two Italian Pediatric Research Networks. Eur J Pediatr 2020; 179: 1315-23.
 
32.
Ouldali N, Yang DD, Madhi F, et al. Factors associated with severe SARS-CoV-2 infection. Pediatrics 2021; 147: e2020023432.
 
33.
Newman AM, Jhaveri R, Patel AB, Tan TQ, Toia JM, Arshad M. Trisomy 21 and coronavirus disease 2019 in pediatric patients. J Pediatr 2021; 228: 294-6.
 
34.
Ku JH, Levin MJ, Luo Y, et al. Risk of severe coronavirus disease 2019 disease in individuals with Down syndrome: a matched cohort study from a large, integrated health care system. J Infect Dis 2022; 226: 757-65.
 
35.
Kompaniyets L, Agathis NT, Nelson JM, et al. Underlying medical conditions associated with severe COVID-19 illness among children. JAMA Netw Open 2021; 4: e2111182.
 
36.
Wallace B, Chang D, Woodworth K, et al. Illness severity indicators in newborns by COVID-19 status in the United States, March-December 2020. J Perinatol 2022; 42: 446-53.
 
37.
Czajka H, Zapolnik P, Krzych Ł, et al. A multi-center, randomised, double-blind, placebo-controlled phase III clinical trial evaluating the impact of BCG re-vaccination on the incidence and severity of SARS-CoV-2 infections among symptomatic healthcare professionals during the COVID-19 Pandem. Vaccines 2022; 10: 314.
 
eISSN:1896-9151
ISSN:1734-1922
Journals System - logo
Scroll to top